Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

NCT01790308 on ClinicalTrials.gov · last registry update 2013-02-13

100 participants. Its estimated completion date, December 2014, has passed with no update to the record. Primary outcome, as filed: the percentage of the patients who maintain glucose control 1 year after short intensive therapy. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Sun Yat-sen University
Sponsor type: Other
Enrollment: 100
Started: 2013-02
Primary completion: 2014-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

the percentage of the patients who maintain glucose control 1 year after short intensive therapy

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.